No added toxicity by immunotherapy. Median progression-free survival (PFS) = 13 m. Median follow-up 17 m, median OS was not reached. Estimated OS at 30 m was 58%.
5 y-OS = 83% (AST) in mEHT vs. 5 y-OS = 25% by BSC. 5 y-OS = 3.5% in mEHT vs. 5 y-OS = 1.2% by BSC for GBM. Median OS = 14 m of mEHT for GBM and OS = 16.5 m for AST.
Random. Phase III chemoradiation alone CHR and mEHT group (mEHT + CHR) [preliminary data]
Preliminary data for the first 100 participants. A positive trend in survival and local disease control by mEHT. No significant differences in acute adverse events or QoL between the groups.
The complete metabolic response (CMR) of disease outside the radiation field at 6 m posttreatment shows the abscopal effect, significantly associated with the addition of mEHT.
Random. Phase III chemoradiation alone [108] and mEHT group (mEHT + CHR) [preliminary data]
Compliance to mEHT treatment was high (97% completed ≥8 treatments) with no significant differences in CRT-related toxicity between treatment groups or between HIV-positive and HIV-negative participants.
Six-month local disease-free survival (LDFS) = 38.6% for mEHT and LDFS = 19.8% without mEHT (). Local disease control (LDC) = 45.5% with mEHT LDC = 24.1% without mEHT; ().
Two centres PFY (), HTT (), control (). 80% (PFY), 80% (HTT) had distant metastases, conventional therapies failed. Median OS = 16.4 m (PFY), 15.6 m (HTT), 14 m (control); first-year survival 67.2% (PFY), 64% (HTT), 26.5% (control).
mEHT + traditional Chinese medicine (TCM) compared to intraperitoneal chemoinfusion [19]
The objective response rate (OPR) = 77.7% in study group (mEHT + TCM) vs. OPR = 63.8% in the ICI group. The QoL = 49.2% vs. 32.3% in the active and control group. Adverse effect rate (AER) = 2.3% vs. 12.3%.
After 3 m, PR = 22 (64.7%), SD = 10 (29.4%), PD = 2 (8.3%) with mEHT after 3 m of the therapy. In group without mEHT in the same time: PR = 3 (8.3%), SD = 10 (27.8%), PD = 23 (34.3%). The median OS = 18 m with mEHT and OS = 10.9 m without mEHT.
Two centres PFY (), HTT (), control (). 59% (PFY), 88% (HTT) had distant metastases, conventional therapies failed. Median OS = 12.0 m (PFY), 12.7 m (HTT), 6.5 m (control); first-year survival 46.2% (PFY), 52.1% (HTT), 26.5% (control). QoL was improved.
OS and time to progression (TTP) were influenced by the number of chemotherapy cycles () and mEHT sessions (). Bevacizumab-based chemotherapy with mEHT had a favourable tumor response, was feasible and well-tolerated in metastatic cancer patients.
CR = 2 (6.1%), very good PR = 5 (15.2%), PR = 13 (39.4%), SD = 9 (27.3%), PD = 4 (12.1%). Three patients (9.1%) developed autoimmune toxicities. All three patients had long-lasting abscopal responses outside the irradiated area.